Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 8/20 | 0.67 |
| ▸ | KCNQ2 | O43526 | 8/20 | 0.67 |
| ▸ | KCNE1 | P15382 | 6/20 | 0.57 |
| ▸ | KCNQ1 | P51787 | 6/20 | 0.57 |
| ▸ | BACE1 | P56817 | 1/20 | 0.57 |
| ▸ | P4HTM | Q9NXG6 | 3/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.55 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.55 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.50 |
| ▸ | MITF | O75030 | 1/20 | 0.49 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.48 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3081735 | 0.91 | KCNQ3 (0.58) | KCNQ3KCNQ2P4HTMPTPN1PTPN6 | |
| SCHEMBL3096952 | 0.88 | KCNQ3 (0.67) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL11326868 | 0.84 | KCNQ3 (0.67) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL3094028 | 0.83 | KCNQ3 (0.65) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL3076566 | 0.82 | PTPN1 (0.73) | PTPN1MAPTKMT2AMITFNPC1 | |
| SCHEMBL27583806 | 0.82 | PTPN1 (0.73) | PTPN1MAPTKMT2AMITFNPC1 | |
| SCHEMBL5213995 | 0.81 | KCNQ3 (0.77) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL14339872 | 0.80 | KCNQ3 (1.00) | KCNQ3KCNQ2KCNE1KCNQ1CYP11B1 | |
| SCHEMBL13210699 | 0.79 | KMT2A (0.73) | PTPN1MAPTKMT2AKDM4ENPC1 | |
| SCHEMBL3096639 | 0.79 | KCNQ3 (0.52) | KCNQ3KCNQ2P4HTMKMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234377-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | EVOTEC AG (DE) | 2010-09-16 | — | — | US | claimed |
| EP-2150532-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | Evotec AG (DE) | 2010-02-10 | — | — | EP | claimed |
| WO-2008122787-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | EVOTEC AG (DE) | 2008-10-16 | — | — | WO | claimed |
| US-20100234377-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | EVOTEC AG (DE) | 2010-09-16 | — | — | US | disclosed |
| EP-2150532-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | Evotec AG (DE) | 2010-02-10 | — | — | EP | disclosed |
| WO-2008122787-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | EVOTEC AG (DE) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234377-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | HPGDS, PTGDR, PTGIS | KCNQ3 3210/4885KCNQ2 2606/4885KCNE1 2255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.